ORGANOVO HOLDINGS INC (ONVO)

US68620A2033 - Common Stock

0.3853  -0.05 (-10.6%)

Fundamental Rating

2

Overall ONVO gets a fundamental rating of 2 out of 10. We evaluated ONVO against 561 industry peers in the Biotechnology industry. ONVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ONVO is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ONVO has reported negative net income.
In the past year ONVO has reported a negative cash flow from operations.
In the past 5 years ONVO always reported negative net income.
In the past 5 years ONVO always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -185.70%, ONVO is not doing good in the industry: 89.55% of the companies in the same industry are doing better.
The Return On Equity of ONVO (-340.82%) is worse than 76.40% of its industry peers.
Industry RankSector Rank
ROA -185.7%
ROE -340.82%
ROIC N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

ONVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ONVO has more shares outstanding
ONVO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ONVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ONVO has an Altman-Z score of -76.14. This is a bad value and indicates that ONVO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ONVO (-76.14) is worse than 96.58% of its industry peers.
There is no outstanding debt for ONVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -76.14
ROIC/WACCN/A
WACC10.67%

2.3 Liquidity

A Current Ratio of 1.98 indicates that ONVO should not have too much problems paying its short term obligations.
ONVO has a Current ratio of 1.98. This is in the lower half of the industry: ONVO underperforms 75.86% of its industry peers.
ONVO has a Quick Ratio of 1.72. This is a normal value and indicates that ONVO is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ONVO (1.72) is worse than 78.92% of its industry peers.
Industry RankSector Rank
Current Ratio 1.98
Quick Ratio 1.72

More info and screens

4

3. Growth

3.1 Past

ONVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.29%, which is quite impressive.
The Revenue for ONVO has decreased by -72.16% in the past year. This is quite bad
Measured over the past years, ONVO shows a very negative growth in Revenue. The Revenue has been decreasing by -48.77% on average per year.
EPS 1Y (TTM)50.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.57%
Revenue 1Y (TTM)-72.16%
Revenue growth 3YN/A
Revenue growth 5Y-48.77%
Sales Q2Q%N/A

3.2 Future

ONVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.47% yearly.
Based on estimates for the next years, ONVO will show a very strong growth in Revenue. The Revenue will grow by 45.71% on average per year.
EPS Next Y55.75%
EPS Next 2Y25.26%
EPS Next 3Y14.47%
EPS Next 5YN/A
Revenue Next Year126.67%
Revenue Next 2Y63.71%
Revenue Next 3Y45.71%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ONVO's earnings are expected to grow with 14.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.26%
EPS Next 3Y14.47%

More info and screens

0

5. Dividend

5.1 Amount

ONVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOVO HOLDINGS INC

NASDAQ:ONVO (1/10/2025, 10:03:02 AM)

0.3853

-0.05 (-10.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)N/A N/A
Inst Owners20.2%
Inst Owner Change0%
Ins Owners1.23%
Ins Owner Change4.35%
Market Cap5.92M
Analysts45.71
Price Target5.51 (1330.05%)
Short Float %0.76%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.44%
Min EPS beat(2)31.67%
Max EPS beat(2)47.21%
EPS beat(4)4
Avg EPS beat(4)30.51%
Min EPS beat(4)10.87%
Max EPS beat(4)47.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.28%
Min Revenue beat(2)-28.26%
Max Revenue beat(2)-18.3%
Revenue beat(4)0
Avg Revenue beat(4)-50.53%
Min Revenue beat(4)-93.46%
Max Revenue beat(4)-18.3%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.67%
EPS NY rev (1m)0%
EPS NY rev (3m)19.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-99.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 57.5
P/FCF N/A
P/OCF N/A
P/B 1.61
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.01
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -185.7%
ROE -340.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.4%
Cap/Sales 14.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.98
Quick Ratio 1.72
Altman-Z -76.14
F-Score2
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)148.6%
Cap/Depr(5y)294.16%
Cap/Sales(3y)57.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.57%
EPS Next Y55.75%
EPS Next 2Y25.26%
EPS Next 3Y14.47%
EPS Next 5YN/A
Revenue 1Y (TTM)-72.16%
Revenue growth 3YN/A
Revenue growth 5Y-48.77%
Sales Q2Q%N/A
Revenue Next Year126.67%
Revenue Next 2Y63.71%
Revenue Next 3Y45.71%
Revenue Next 5YN/A
EBIT growth 1Y34.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.14%
OCF growth 3YN/A
OCF growth 5YN/A